Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Melanoma 1

Interventions

Specimen Handling 278pembrolizumab 228Magnetic Resonance Spectroscopy 228Carboplatin 180Biopsy 168Cisplatin 166Nivolumab 160Cyclophosphamide 144Radiotherapy 126Paclitaxel 124Gemcitabine 116Bevacizumab 96durvalumab 92Dexamethasone 88Rituximab 81Oxaliplatin 80venetoclax 75atezolizumab 74Capecitabine 71Fluorouracil 70Docetaxel 70Doxorubicin 68Etoposide 65Radiosurgery 64Ipilimumab 64Radiation 62Prednisone 61Cytarabine 60Lenalidomide 58Pemetrexed 55

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × naporafenib × 90 days × Clear all
NCT04417621 2026-03-12

Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma

Novartis

Phase 2 Active not recruiting
134 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡